They allow users to quickly add new devices to their surveillance networks without the need of buying new hardware.
Currently, all subscription licenses come with a free replacement cycle: you are able to cancel your subscription and renew your license at any time without the need to pay a fee.
Reasons for subscribing to a Surveillance Device License Pack
Expansion: new hardware can be added with as few as two video sources, one access controller and a transaction device.
Device management: You can keep track of your license status online and exchange firmware easily.
Advanced control: control the camera or the intercom of a subscription-based license from the web interface of your device.
Additional security: using device-based authentication, users are required to enter a valid license code before accessing a monitored device. This makes it easier to track unauthorized devices, as they will not be able to gain access to your system.
Renewal
To renew your subscription, go to your device settings, click on the tab License then select the renewal option on the right side.
You will be presented with a number of options:
Package: the subscription license type (whether you are a reseller, an end user, or a third party)
Renewal period: The maximum period in days for which your subscription can be renewed, limited to a maximum of 365 days. If you do not renew your subscription, you can cancel your subscription at any time.
Renew: renew the subscription or cancel it.
Delete: delete your existing subscription or renew it.
Note: When you delete your subscription, all licenses are terminated and the first license you renew will expire.Evaluation of the premarket screening and development of an oral dosage form of a novel renin inhibitor based on application of a classical biopharmaceutical approach.
We developed and evaluated the potential of a preclinical pharmacokinetic/pharmacodynamic (PK/PD) approach to developing and optimizing a novel renin inhibitor for further investigation in clinical trials. A double-blind, randomized, placebo-controlled, crossover study was conducted in healthy human volunteers to evaluate the bioavailability of two oral formulations containing a renin inhibitor with a novel chemical structure in comparison to the reference oral drug (sitaxsentan) on the basis of plasma renin activity (PRA), angiotensin converting enzyme (ACE) inhibition and biometrical parameters. The following formulations were compared: (i) the
Related links:
コメント